1-855-378-42281-855-378-4228
One of the outpatient rehabilitation alternatives for individuals in Lincoln who are battling with opioid abuse and addiction is called opioid maintenance therapy. Licensed facilities and doctors are authorized to give specific medications to opioid addicted people, many that are opioids themselves and are habit forming. In low enough amounts the client does not experience high feelings but also does not experience intense cravings and is not experiencing opioid withdrawal. Methadone is the first drug used for this purpose, but there are other options currently to select from.
Methadone is an opiate and can be taken at an outpatient clinic licensed to dispense the drug, that is taken on a daily basis as a pill or liquid. The price of the drug is around one hundred and fifty dolloars a month. Buprenorphine is also an opiate based med, and is in pill form often taken one day on, one day off. But unlike Methadone which can only be administered in highly structured medical centers, Buprenorphine can be and is prescribed and dispensed in doctor's offices. The monthly cost of buprenorphine is around $300 /month for the generic version of the drug. There is also a type of buprenorphine containing the drug naloxone, which is a drug which reverses the effects of opiates. An individual consuming this version of the drug, AKA Suboxone, would find it more difficult to feel high from opioids if they relapsed while taking the drug. It is also taken on a daily basis, and is priced around $450 /month. Naltrexone is an additional drug used in opioid maintenance therapy, but unlike the other drugs mentioned it is an opiate blocker and is not an opioid. There is an option to take this medication as a monthly injection, which is called Vivitrol. As an opioid blocker, the drug prevents someone from getting high from opioids, and in turn lowers the risk associated with relapse. This daily shot costs in the range of $1000 to $1200 per month.
For All Drug and Alcohol Treatment Programs In Lincoln, Click Here.
